Active surveillance in prostate cancer: role of available biomarkers in daily practice
Resumen: Prostate cancer (PCa) is the most commonly diagnosed cancer in men. The diagnosis is currently based on PSA levels, which are associated with overdiagnosis and overtreatment. Moreover, most PCas are localized tumours; hence, many patients with low-/very low-risk PCa could benefit from active surveillance (AS) programs instead of more aggressive, active treatments. Heterogeneity within inclusion criteria and follow-up strategies are the main controversial issues that AS presently faces. Many biomarkers are currently under investigation in this setting; however, none has yet demonstrated enough diagnostic ability as an independent predictor of pathological or clinical progression. This work aims to review the currently available literature on tissue, blood and urine biomarkers validated in clinical practice for the management of AS patients.
Idioma: Inglés
DOI: 10.3390/ijms22126266
Año: 2021
Publicado en: International Journal of Molecular Sciences 22, 12 (2021), 6266 [14 pp.]
ISSN: 1661-6596

Factor impacto JCR: 6.208 (2021)
Categ. JCR: BIOCHEMISTRY & MOLECULAR BIOLOGY rank: 69 / 297 = 0.232 (2021) - Q1 - T1
Categ. JCR: CHEMISTRY, MULTIDISCIPLINARY rank: 50 / 180 = 0.278 (2021) - Q2 - T1

Factor impacto CITESCORE: 6.9 - Computer Science (Q1) - Chemical Engineering (Q1) - Medicine (Q1) - Biochemistry, Genetics and Molecular Biology (Q2)

Factor impacto SCIMAGO: 1.176 - Computer Science Applications (Q1) - Inorganic Chemistry (Q1) - Spectroscopy (Q1) - Organic Chemistry (Q1) - Physical and Theoretical Chemistry (Q1) - Molecular Biology (Q1)

Tipo y forma: Review (Published version)
Área (Departamento): Área Urología (Dpto. Cirugía)
Exportado de SIDERAL (2023-05-18-14:30:04)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
articulos



 Notice créée le 2021-09-13, modifiée le 2023-05-19


Versión publicada:
 PDF
Évaluer ce document:

Rate this document:
1
2
3
 
(Pas encore évalué)